Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.23+0.36 (+12.54%)
Close on Nov 16, 2026Market cap $265.01MP/E –Yield –
Lexeo Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lexeo Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$94.82M. For fiscal 2025 it was -$108.99M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$108.99M | – |
| FY2024 | Dec 31, 2024 | -$105.46M | – |
| FY2023 | Dec 31, 2023 | -$68.24M | – |
| FY2022 | Dec 31, 2022 | -$60.39M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$27.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.14M | – |
See a number that looks wrong?